The Centers for Disease Control and Prevention (CDC) continues to refine public health strategies for managing monkeypox, also known as mpox, as of February 10, 2026, emphasizing collaboration between clinical staff, health departments, and the agency itself. This ongoing effort reflects lessons learned from recent outbreaks and a commitment to adapting guidance based on evolving epidemiological data.
According to the CDC, health departments remain central to mpox management, irrespective of the viral clade. The agency is focused on providing updated recommendations for clinical and public health management, encompassing prevention, case reporting, testing, treatment, and infection control protocols. This guidance is subject to change as new information emerges from investigations both within the United States and internationally.
The CDC highlights the importance of infection prevention and control (IPC) measures in clinical settings, patient homes, and within the broader community. Resources are available regarding hand hygiene and the proper leverage of personal protective equipment (PPE). Specific guidance addresses isolation and infection control within households, as well as risk assessment and monitoring procedures for both community and healthcare settings. The agency also provides guidance on handling human remains of patients who have died from mpox.
Current CDC focus includes providing resources for non-U.S. And resource-limited settings, acknowledging the global implications of mpox outbreaks. The agency is also addressing specific concerns such as mpox infections involving the eyes, with interim guidance available for symptomatic management. Separate guidance is available for the management of children and adolescents with exposure to, suspicion of, or confirmed cases of mpox.
A recent review published in ScienceDirect underscores the need for strengthened public healthcare systems to prepare for potential mpox outbreaks, drawing lessons from the COVID-19 pandemic. The review details the aetiopathogenesis, clinical features, and laboratory diagnosis of mpox, alongside outbreak preparedness measures.
Clinical management of mpox, regardless of clade, is determined by the severity of the patient’s condition at diagnosis and the presence of complicating factors. The CDC continues to collaborate with partners to provide updates on mpox management, surveillance, laboratory testing, and clinical guidance.
